Haibin Luo, PhD

Director of Downstream Process Development, BioPharmaceutical Development at AstraZeneca

Speaker

Dr. Haibin Luo severs as a director in the Pharmaceutical Development organization at AstraZeneca, specializing in downstream process development for novel biologics (such as inhaled biologics and T-cell engagers), protein characterization, and safety risk assessment for process-related impurities. He has 13-year experience in downstream process development for early-to-late-stage drugs and regulatory filings, as well as 2-year experience on CMC team leadership. He published more than 20 papers on protein purification and characterization. He earned his PhD in Drug Design & Development from Chinese Academy of Sciences in 2006.